[
  ', 
      ', 
        ', 
          ', 
            ', 
              ', Genticel',             ', 
          ', 
        ', 
        ', 
          		', 
						

', 
	', 
		', 
			', 
						

', 
	', INNOVATIVE IMMUNOTHERAPIES', 
TO FIGHT INFECTIOUS DISEASES AND CANCER', 
		', 
			', 
						', 

	', 
						', 
			', 
							', 						', 
			', 
								', 
			', 
							', 						', 
			', 
				', 

', 
		', 
			', 
						', 
	', 
		',  ',  ',  ', 		', 
		', 
		', 
	', 
', 
		', 
			', 
						
', 
', Home',  > ', Company',  > ', Partnerships', 
		', 
	
          		', 
						
			', 
	', 
        ', 
        ', 
            ', 
								', \u2261', 				', Home', 
		', Company', 
	', 
	', Management', 
		', Supervisory Board', 
		', Clinical Advisory Board', 
		', Partnerships', 
	', 
	', 
	', 
	', Technology', 
	', 
	', CyaA', 
		', Vaxiclase', 
	', 
	', 
	', 
	', Products', 
	', 
	', GTL001 - GTL002 (HPV)', 
		', GTL003 (Empty Vaxiclase vector used as a Pertussis antigen)', 
	', 
	', 
	', 
	', Investors', 
	', 
	', Welcome', 
		', Stock information', 
		', Analyst coverage', 
		', Press releases', 
		', Events & Presentations', 
		', Financial information', 
		', Regulated Information', 
		', Shareholder information', 
	', 
	', General meeting', 
		', Shareholder Newsletter', 
	', 
	', 
	', 
	', Corporate governance', 
	', 
	', Supervisory Board', 
		', Board committees', 
	', 
	', 
	', 
	', 
	', 
	', 
	', News & Events', 
	', 
	', News', 
		', Events', 
	', 
	', 
	', 
	', Contribution project',             ', 
        ', 
        ', 
        ', 
    ', 
    ', 
		', 
	
        ', 
      ', 
      ', 
        ', 
          ', 
            		', 
						
', 
', Management', Supervisory Board', Clinical Advisory Board', Partnerships', 
		', 
			', 
						

', 
	', 
', Email alerts', 
', 
', Contact us', 
		', 
	
          ', 
           ', 
	', 
	
		
						
	
	
				
								', 
		', 
  ', Partnerships', 
', 
', 
  ', Genticel is highly interested in to developing relationships with partners.', 
', 
', 
', Become a partner', 
', 
', If you have a partnering opportunity in our area of expertise or an interest in our products, please contact us at ', This email address is being protected from spambots. You need JavaScript enabled to view it.', u"
				document.getElementById('cloak6527c63c953ed8242825e4a9a3244ca1').innerHTML = '';
				var prefix = '&#109;a' + 'i&#108;' + '&#116;o';
				var path = 'hr' + 'ef' + '=';
				var addy6527c63c953ed8242825e4a9a3244ca1 = 'b&#117;s&#105;n&#101;ss' + '&#64;';
				addy6527c63c953ed8242825e4a9a3244ca1 = addy6527c63c953ed8242825e4a9a3244ca1 + 'g&#101;nt&#105;c&#101;l' + '&#46;' + 'c&#111;m';
				var addy_text6527c63c953ed8242825e4a9a3244ca1 = 'b&#117;s&#105;n&#101;ss' + '&#64;' + 'g&#101;nt&#105;c&#101;l' + '&#46;' + 'c&#111;m';document.getElementById('cloak6527c63c953ed8242825e4a9a3244ca1').innerHTML += '<a ' + path + '\'' + prefix + ':' + addy6527c63c953ed8242825e4a9a3244ca1 + '\'>'+addy_text6527c63c953ed8242825e4a9a3244ca1+'<\/a>';
		", 
', 
', 
  ', Read more on our partnership with Serum Institute of India Pvt. Ltd', 
  ', 
    ', In February 2015, Genticel licensed, to Serum Institute of India Ltd. (Serum Institute) GTL003, its Vaxiclase technology for use as an antigenfor use in the development of acellular multivalent combination vaccines containing pertussis antigens.', 
    ', Serum Institute of India (', www.seruminstitute.com', u") is a private company valued at over $12 billion and the world's largest producer of the Measles and DTP group of vaccines. Two of every three children immunized globally are vaccinated with a product manufactured by Serum Institute.", 
    ', The license granted by Genticel to Serum Institute provides GTL003 for its inclusion in multivalent vaccines that also protect against Bordetella pertussis, the causative agent of whooping cough. The license covers all countries of the world except major pharmaceutical markets, in particular the USA, Canada, New Zealand, Australia, Japan, Israel, Turkey and greater Europe.', 
    ', In exchange for the access and use of GTL003 in the licensed indication, Genticel is eligible for up to $57 million in upfront, development & sales milestone payments from Serum Institute, as well as single digit royalties on net sales.', 
    ', In November 2016, the last preclinical milestone in the partnership was reached, opening the path to formal preclinical testing prior to clinical development and subsequent commercialization.', 
  ', 
  ', end faq', 
  ', 
',  	', 

	
							', 


  ', 
        ', 

        ', 
          		', 
						
', 
', Home', Company', Management', Supervisory Board', Clinical Advisory Board', Partnerships', Technology', CyaA', Vaxiclase', Products', GTL001 - GTL002 (HPV)', GTL003 (Vaxiclase as an antigen)', Investors', Welcome', Stock information', Analyst coverage', Press releases', Events & Presentations', Financial information', Regulated Information', Shareholder information', Corporate governance', News & Events', News', Events', 
		', 
			', 
						

', 
	',  ', Headquarters and Laboratories',  Prologue-Biotech',  516 rue Pierre et Marie Curie',  31670 Labège',  FRANCE',  ',  Tel: +33 5 61 28 70 60',  Fax: +33 5 61 28 70 69', 
', 
', Paris Offices',  5 rue Tronchet',  75008 Paris',  FRANCE', 
', 
		', 
	
        ', 
      ', 
  ', 
      ', 
        		', 
						', 
var positionElementInPage = $('#maximenuck').offset().top;
jQuery(document).ready(function($) {
	$(window).scroll(function(){
		if ($(window).scrollTop() >= positionElementInPage) {
			// fixed
			$('#maximenuck').addClass("floatable");
		} else {
			// relative
			$('#maximenuck').removeClass("floatable");
		}
	});
});
', 		', 
			', 
						
', 
', Contact', Site map', Legal terms', 
		', 
			', 
						

', 
	',  ', 
', 
		', 
			', 
						

', 
	© Genticel 2015. All rights reserved.', 
		', 
	
      ', 
      ', 
        ', 
        ', Design and production ', Actusnews', 
        ', 
      ', 
  ', 
', Cookies are small text files downloaded to your computer each time you visit a website. When you return to websites, or you visit websites using the same cookies, they accept these cookies and therefore your computer or mobile device.', Read More', I accept', /*<![CDATA[*/var name = "fmalertcookies" + "=";var ca = document.cookie.split(";");var acceptCookie = false;for(var i=0; i<ca.length; i++) {var c = ca[i];while (c.charAt(0)==" ") c = c.substring(1);if (c.indexOf(name) == 0){ acceptCookie = true; document.getElementById("cadre_alert_cookies").style.display="none";}}var d = new Date();d.setTime(d.getTime() + (30*(24*60*60*1000)));var expires_cookie = "expires="+d.toUTCString();function CloseCadreAlertCookie(){document.getElementById('cadre_alert_cookies').style.display='none'; document.cookie='fmalertcookies=true; '+expires_cookie+'; path=/';}/*]]>*/'][
  ', 
      ', 
        ', 
          ', 
            ', 
              ', Genticel',             ', 
          ', 
        ', 
        ', 
          		', 
						

', 
	', 
		', 
			', 
						

', 
	', INNOVATIVE IMMUNOTHERAPIES', 
TO FIGHT INFECTIOUS DISEASES AND CANCER', 
		', 
			', 
						', 

	', 
						', 
			', 
							', 						', 
			', 
								', 
			', 
							', 						', 
			', 
				', 

', 
		', 
			', 
						', 
	', 
		',  ',  ',  ', 		', 
		', 
		', 
	', 
', 
		', 
			', 
						
', 
', Home',  > ', Company',  > ', Partnerships', 
		', 
	
          		', 
						
			', 
	', 
        ', 
        ', 
            ', 
								', \u2261', 				', Home', 
		', Company', 
	', 
	', Management', 
		', Supervisory Board', 
		', Clinical Advisory Board', 
		', Partnerships', 
	', 
	', 
	', 
	', Technology', 
	', 
	', CyaA', 
		', Vaxiclase', 
	', 
	', 
	', 
	', Products', 
	', 
	', GTL001 - GTL002 (HPV)', 
		', GTL003 (Empty Vaxiclase vector used as a Pertussis antigen)', 
	', 
	', 
	', 
	', Investors', 
	', 
	', Welcome', 
		', Stock information', 
		', Analyst coverage', 
		', Press releases', 
		', Events & Presentations', 
		', Financial information', 
		', Regulated Information', 
		', Shareholder information', 
	', 
	', General meeting', 
		', Shareholder Newsletter', 
	', 
	', 
	', 
	', Corporate governance', 
	', 
	', Supervisory Board', 
		', Board committees', 
	', 
	', 
	', 
	', 
	', 
	', 
	', News & Events', 
	', 
	', News', 
		', Events', 
	', 
	', 
	', 
	', Contribution project',             ', 
        ', 
        ', 
        ', 
    ', 
    ', 
		', 
	
        ', 
      ', 
      ', 
        ', 
          ', 
            		', 
						
', 
', Management', Supervisory Board', Clinical Advisory Board', Partnerships', 
		', 
			', 
						

', 
	', 
', Email alerts', 
', 
', Contact us', 
		', 
	
          ', 
           ', 
	', 
	
		
						
	
	
				
								', 
		', 
  ', Partnerships', 
', 
', 
  ', Genticel is highly interested in to developing relationships with partners.', 
', 
', 
', Become a partner', 
', 
', If you have a partnering opportunity in our area of expertise or an interest in our products, please contact us at ', This email address is being protected from spambots. You need JavaScript enabled to view it.', u"
				document.getElementById('cloakc6ca9beeb6401585debf4094c6302317').innerHTML = '';
				var prefix = '&#109;a' + 'i&#108;' + '&#116;o';
				var path = 'hr' + 'ef' + '=';
				var addyc6ca9beeb6401585debf4094c6302317 = 'b&#117;s&#105;n&#101;ss' + '&#64;';
				addyc6ca9beeb6401585debf4094c6302317 = addyc6ca9beeb6401585debf4094c6302317 + 'g&#101;nt&#105;c&#101;l' + '&#46;' + 'c&#111;m';
				var addy_textc6ca9beeb6401585debf4094c6302317 = 'b&#117;s&#105;n&#101;ss' + '&#64;' + 'g&#101;nt&#105;c&#101;l' + '&#46;' + 'c&#111;m';document.getElementById('cloakc6ca9beeb6401585debf4094c6302317').innerHTML += '<a ' + path + '\'' + prefix + ':' + addyc6ca9beeb6401585debf4094c6302317 + '\'>'+addy_textc6ca9beeb6401585debf4094c6302317+'<\/a>';
		", 
', 
', 
  ', Read more on our partnership with Serum Institute of India Pvt. Ltd', 
  ', 
    ', In February 2015, Genticel licensed, to Serum Institute of India Ltd. (Serum Institute) GTL003, its Vaxiclase technology for use as an antigenfor use in the development of acellular multivalent combination vaccines containing pertussis antigens.', 
    ', Serum Institute of India (', www.seruminstitute.com', u") is a private company valued at over $12 billion and the world's largest producer of the Measles and DTP group of vaccines. Two of every three children immunized globally are vaccinated with a product manufactured by Serum Institute.", 
    ', The license granted by Genticel to Serum Institute provides GTL003 for its inclusion in multivalent vaccines that also protect against Bordetella pertussis, the causative agent of whooping cough. The license covers all countries of the world except major pharmaceutical markets, in particular the USA, Canada, New Zealand, Australia, Japan, Israel, Turkey and greater Europe.', 
    ', In exchange for the access and use of GTL003 in the licensed indication, Genticel is eligible for up to $57 million in upfront, development & sales milestone payments from Serum Institute, as well as single digit royalties on net sales.', 
    ', In November 2016, the last preclinical milestone in the partnership was reached, opening the path to formal preclinical testing prior to clinical development and subsequent commercialization.', 
  ', 
  ', end faq', 
  ', 
',  	', 

	
							', 


  ', 
        ', 

        ', 
          		', 
						
', 
', Home', Company', Management', Supervisory Board', Clinical Advisory Board', Partnerships', Technology', CyaA', Vaxiclase', Products', GTL001 - GTL002 (HPV)', GTL003 (Vaxiclase as an antigen)', Investors', Welcome', Stock information', Analyst coverage', Press releases', Events & Presentations', Financial information', Regulated Information', Shareholder information', Corporate governance', News & Events', News', Events', 
		', 
			', 
						

', 
	',  ', Headquarters and Laboratories',  Prologue-Biotech',  516 rue Pierre et Marie Curie',  31670 Labège',  FRANCE',  ',  Tel: +33 5 61 28 70 60',  Fax: +33 5 61 28 70 69', 
', 
', Paris Offices',  5 rue Tronchet',  75008 Paris',  FRANCE', 
', 
		', 
	
        ', 
      ', 
  ', 
      ', 
        		', 
						', 
var positionElementInPage = $('#maximenuck').offset().top;
jQuery(document).ready(function($) {
	$(window).scroll(function(){
		if ($(window).scrollTop() >= positionElementInPage) {
			// fixed
			$('#maximenuck').addClass("floatable");
		} else {
			// relative
			$('#maximenuck').removeClass("floatable");
		}
	});
});
', 		', 
			', 
						
', 
', Contact', Site map', Legal terms', 
		', 
			', 
						

', 
	',  ', 
', 
		', 
			', 
						

', 
	© Genticel 2015. All rights reserved.', 
		', 
	
      ', 
      ', 
        ', 
        ', Design and production ', Actusnews', 
        ', 
      ', 
  ', 
', Cookies are small text files downloaded to your computer each time you visit a website. When you return to websites, or you visit websites using the same cookies, they accept these cookies and therefore your computer or mobile device.', Read More', I accept', /*<![CDATA[*/var name = "fmalertcookies" + "=";var ca = document.cookie.split(";");var acceptCookie = false;for(var i=0; i<ca.length; i++) {var c = ca[i];while (c.charAt(0)==" ") c = c.substring(1);if (c.indexOf(name) == 0){ acceptCookie = true; document.getElementById("cadre_alert_cookies").style.display="none";}}var d = new Date();d.setTime(d.getTime() + (30*(24*60*60*1000)));var expires_cookie = "expires="+d.toUTCString();function CloseCadreAlertCookie(){document.getElementById('cadre_alert_cookies').style.display='none'; document.cookie='fmalertcookies=true; '+expires_cookie+'; path=/';}/*]]>*/']